Hls Therapeutics — Q2 2021 Earnings Presentation

6 slides from Hls Therapeutics's earnings presentation, Aug 5, 2021

Slide 1: Q2 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q2 2021 Results Conference Call August 5, 2021 TSX - HLS
Slide 2: Forward-looking statements
Forward-looking statements Certain statements in this presentation are “forward-looking statements”. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performance (often, but not alwa
Slide 3: Vascepa: prescription momentum growing…
Vascepa: prescription momentum growing… Weekly script data since launch …fueled by growth catalysts 600 Private market access 500 • >90% eligible for coverage 400 Inclusion in Canadian medical Prescriptions society guidelines • Canadian Cardiovascular Society, 300 Heart & Stroke, Thrombosis Canada 2
Slide 4: Vascepa Recent Analogues: two-year comparison
Vascepa Recent Analogues: two-year comparison 7% 70,000 The oral anti-coagulant market is a relevant analogue Patients at Peak 6% for Vascepa. It has a similar market size potential and 60,000 overlap of healthcare practitioners 5% 50,000 140K* Total Prescriptions (TRx) Vascepa (projected) % of peak
Slide 5: Q2 2021 Results Conference Call
Gilbert Godin | CEO Tim Hendrickson | CFO Q2 2021 Results Conference Call August 5, 2021 TSX - HLS
Slide 6: Q&A
Q&A TSX - HLS